Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zembrzuska, Hanna
NCT06581198: A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)	Recruiting	2	144	Europe, Japan, US, RoW	rapcabtagene autoleucel Regimen 1, rapcabtagene autoleucel Regimen 2, Standard of Care	Novartis Pharmaceuticals	Lupus Erythematosus, Systemic, Lupus Nephritis	05/29	05/30
NCT06655896: Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis	Recruiting	2	86	Europe, Japan, US, RoW	rapcabtagene autoleucel, rituximab	Novartis Pharmaceuticals	Scleroderma, Diffuse	12/28	12/30
NCT06665256: Phase 2 Study of Rapcabtagene Autoleucel in Myositis	Recruiting	2	123	Japan, US, RoW	Rapcabtagene autoleucel, YTB323, Active Comparator Option	Novartis Pharmaceuticals	Idiopathic Inflammatory Myopathies	07/29	07/30
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)	Recruiting	1/2	30	US, RoW	IMPT-514	ImmPACT Bio	Systemic Lupus Erythematosus, Lupus Nephritis	02/27	02/27
NCT06130540: Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR	Recruiting	1	60	Europe, US, RoW	Secukinumab, AIN457	Novartis Pharmaceuticals	Giant Cell Arteritis, Polymyalgia Rheumatica	05/25	07/25
Donovan, Darby
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)	Recruiting	1/2	30	US, RoW	IMPT-514	ImmPACT Bio	Systemic Lupus Erythematosus, Lupus Nephritis	02/27	02/27